News Room

Cipher Pharmaceuticals completes Canadian distribution and supply agreement for extended-release tramadol CIPHER PHARMACEUTICALS DND 9/26/2011 8:30:00 AM...

  Norgine and Medical Futures are pleased to announce the launch of MOVIPREP®, a bowel cleansing preparation in Canada. “The launch of MOVIPREP® underlines Medical Futures’ commitment to the prevention and treatment of gastrointestinal diseases,” said Colin Campbell, Medical Futures’ CEO.     Commenting on the launch Peter Stein, Norgine’s...

Medical Futures Inc. would like to announce the newest addition to the Medical Futures Inc. team. Colin Campbell will be joining MFI as the new General Manager.   Colin brings over 20 years’ experience as a senior financial and operations executive in the pharmaceutical and biotech industries, including start-up, global...

Ardeypharm GmbH, Herdecke, Germany and Medical Futures Inc (MFI), Canada/USA, recently entered a license agreement for MFI to market Mutaflor® in Canada and USA. Mutaflor® is a probiotic treatment for preventing and/or maintaining remission of ulcerative colitis and for chronic constipation. Under the license Ardeypharm will supply the product while...

Norgine, the leading European specialty pharmaceutical company, has today announced that it has granted Medical Futures the exclusive rights to market MOVIPREP® in Canada.   MOVIPREP is a novel patent-protected product developed by Norgine for bowel cleansing prior to colonoscopy and other situations where a clean bowel is required. The...